Electronic Resource
Palo Alto, Calif.
:
Annual Reviews
Annual Review of Pharmacology
41 (2001), S. 79-99
ISSN:
0362-1642
Source:
Annual Reviews Electronic Back Volume Collection 1932-2001ff
Topics:
Medicine
,
Chemistry and Pharmacology
Notes:
Abstract L-Arginine (2-amino-5-guanidinovaleric acid) is the precursor of nitric oxide, an endogenous messenger molecule involved in a variety of endothelium-mediated physiological effects in the vascular system. Acute and chronic administration of L-arginine has been shown to improve endothelial function in animal models of hypercholesterolemia and atherosclerosis. L-Arginine also improves endothelium-dependent vasodilation in humans with hypercholesterolemia and atherosclerosis. The responsiveness to L-arginine depends on the specific cardiovascular disease studied, the vessel segment, and morphology of the artery. The pharmacokinetics of L-arginine have recently been investigated. Side effects are rare and mostly mild and dose dependent. The mechanism of action of L-arginine may involve nitric oxide synthase substrate provision, especially in patients with elevated levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine. Endocrine effects and unspecific reactions may contribute to L-arginine-induced vasodilation after higher doses. Several long-term studies have been performed that show that chronic oral administration of L-arginine or intermittent infusion therapy with L-arginine can improve clinical symptoms of cardiovascular disease in man.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1146/annurev.pharmtox.41.1.79
| Library |
Location |
Call Number |
Volume/Issue/Year |
Availability |
